DiaMedica Therapeutics (DMAC) Cash from Investing Activities (2018 - 2026)

DiaMedica Therapeutics' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$2.1 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 131.92% year-over-year to -$2.1 million in Q1 2026; TTM through Mar 2026 was -$10.9 million, a 199.54% decrease from a year earlier, with the FY2025 full-year figure at -$2.2 million, down 125.6% from the prior year.
• Cash from Investing Activities retreated to -$2.1 million in Q1 2026 per DMAC's latest filing, from $8.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $9.0 million in Q2 2025 and bottomed at -$28.1 million in Q2 2023.
• The 5-year median for Cash from Investing Activities is $2.5 million (2022), against an average of -$147235.3.
• Across the five-year window, Cash from Investing Activities jumped 24700.0% in 2022 and sank 1212.66% in 2023, its largest moves.
• Year by year, Cash from Investing Activities stood at $4.7 million in 2022, then grew by 29.64% to $6.1 million in 2023, then dropped by 15.01% to $5.2 million in 2024, then surged by 53.6% to $8.0 million in 2025, then tumbled by 126.44% to -$2.1 million in 2026.
• Per Business Quant, the three latest DMAC Cash from Investing Activities figures stand at -$2.1 million (Q1 2026), $8.0 million (Q4 2025), and -$25.8 million (Q3 2025).